Lyell Immunopharma, Inc. (NASDAQ:LYEL) Receives $43.00 Consensus Price Target from Analysts

Lyell Immunopharma, Inc. (NASDAQ:LYEL) has received an average rating of “Moderate Buy” from the seven ratings firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $43.00.

Several equities analysts have issued reports on the stock. Wall Street Zen raised shares of Lyell Immunopharma from a “sell” rating to a “hold” rating in a research note on Sunday, May 10th. Citigroup restated a “market outperform” rating on shares of Lyell Immunopharma in a research note on Tuesday, June 9th. HC Wainwright reaffirmed a “buy” rating and issued a $45.00 target price on shares of Lyell Immunopharma in a report on Tuesday, June 9th. Citizens Jmp reiterated a “market outperform” rating and set a $34.00 price target on shares of Lyell Immunopharma in a research note on Monday, June 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Lyell Immunopharma in a research note on Friday.

Hedge Funds Weigh In On Lyell Immunopharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BBR Partners LLC acquired a new stake in shares of Lyell Immunopharma in the 4th quarter valued at approximately $210,000. ExodusPoint Capital Management LP acquired a new position in Lyell Immunopharma during the fourth quarter worth $262,000. Marshall Wace LLP acquired a new position in Lyell Immunopharma during the second quarter worth $94,000. Jane Street Group LLC purchased a new position in Lyell Immunopharma in the fourth quarter worth $382,000. Finally, Barclays PLC raised its position in Lyell Immunopharma by 1,239.5% in the fourth quarter. Barclays PLC now owns 15,967 shares of the company’s stock worth $491,000 after acquiring an additional 14,775 shares in the last quarter. Institutional investors and hedge funds own 66.05% of the company’s stock.

Lyell Immunopharma Trading Up 1.5%

Lyell Immunopharma stock opened at $13.11 on Friday. The stock has a 50 day moving average of $14.50 and a two-hundred day moving average of $20.07. Lyell Immunopharma has a twelve month low of $9.28 and a twelve month high of $45.00. The stock has a market capitalization of $321.19 million, a price-to-earnings ratio of -0.95 and a beta of -0.06.

Lyell Immunopharma (NASDAQ:LYEL) last released its earnings results on Wednesday, May 6th. The company reported ($1.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($1.10). Lyell Immunopharma had a negative return on equity of 85.71% and a negative net margin of 794,858.12%.The business had revenue of $0.00 million for the quarter, compared to analyst estimates of $0.00 million. Equities analysts predict that Lyell Immunopharma will post -7.87 earnings per share for the current year.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.